Forte Biosciences
FBRX
58 hedge funds and large institutions have $4.38M invested in Forte Biosciences in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 21 closing their positions.
133% more call options, than puts
Call options by funds: $363K | Put options by funds: $156K
0.02% less ownership
Funds ownership: 0.09% → 0.07% (-0.02%)
22% less funds holding
Funds holding: 74 → 58 (-16)
30% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 20
71% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 21
92% less capital invested
Capital invested by funds: $56.4M → $4.38M (-$52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
+$2.29M |
| 2 |
Renaissance Technologies
New York
|
+$1.44M |
| 3 |
State Street
Boston,
Massachusetts
|
+$897K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$592K |
| 5 |
D.E. Shaw & Co
New York
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.48M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$3.79M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.35M |
| 4 |
6CM
683 Capital Management
New York
|
-$2.5M |
| 5 |
JP Morgan Chase
New York
|
-$1.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PPA
76
Parametric Portfolio Associates
Seattle,
Washington
| – | -$75K | -30 | Closed |
|
77
Creative Planning
Overland Park,
Kansas
| – | -$72K | -29 | Closed |
|
78
First Manhattan
New York
| – | -$13K | -5 | Closed |
|
|
MAM
79
Meeder Asset Management
Dublin,
Ohio
| – | -$3.04K | -2 | -67% |
|
|
PCP
80
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -1 | Closed |
|
FBRX Hedge Fund Activity: Q3 2019 in Review
58 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2019, worth a combined $4.38M — down 92% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of FBRX and 6 opened new positions — a net loss of 15 holders — while 20 trimmed existing stakes and 14 added.
The largest buyer was ISZO Capital Management, opening a new position worth an estimated $2.29M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.48M sold.
- 58 institutional investors held Forte Biosciences (FBRX) as of Q3 2019, down from 74 in Q2 2019.
- Funds reported $4.38M of Forte Biosciences stock for Q3 2019, down 92% quarter-over-quarter.
- 6 funds opened new Forte Biosciences positions in Q3 2019 and 21 closed out, a net change of -15 holders.
- The largest Forte Biosciences buyer in Q3 2019 was ISZO Capital Management, an estimated $2.29M added.
- The largest Forte Biosciences seller in Q3 2019 was Sectoral Asset Management, an estimated $4.48M sold.
Based on aggregated 13F filings for Q3 2019.